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Early intensive treatment normalises excess 
mortality in ACPA-negative RA but not in ACPA-
positive RA
With great interest, we read the recently published report by 
Poppelaars et al in which no excess mortality was observed in 
155 patients with rheumatoid arthritis (RA) from the COmbi-
natie therapie Bij Rheumatoide Artritis (COBRA)-trial, who 
received early intensive treatment, compared with the general 
population (Standardised mortality rate (SMR) 0.80 (0.59–
1.06)).1 The question whether mortality in RA has normalised 
is debated, as contradicting results have been published.2–8 In 
many of the studies on mortality, two important factors are not 
sufficiently taken into account: follow-up duration and disease 
subtypes. This might explain the conflicting results. Because thus 
far none of the reported studies incorporated both factors in the 
analyses, it is too soon to conclude that mortality is ‘normal’ 
again, as we will show here.
We compliment the authors on emphasising the importance 
of a long follow-up duration by showing in their meta-anal-
ysis that excess mortality in RA becomes fully apparent after 
>10 years. This implies that previous studies that reported on 
normalisation of mortality had insufficient follow-up to reach 
this conclusion.2–5 Some studies with a short follow-up duration 
even showed a seemingly decreased mortality in RA, which may 
be due to a healthy inclusion bias.3–5
RA consists of two subtypes that are characterised by the 
presence or absence of RA-related autoantibodies, of which 
the presence of anti-citrullinated protein antibodies (ACPA) is 
most specific for RA. Both subtypes have known differences 
in the severity of the disease course. The study of Poppelaars 
et al did not stratify for ACPA, which is due to a small sample 
size (n=155), leaving the question unanswered if mortality has 
normalised in both subsets of RA.
To assess the true impact of early intensive treatment on 
mortality, we performed a large study with up to 25 years of 
follow-up and sufficient power to stratify for ACPA. One thou-
sand two hundred and eighty-eight patients with RA fulfilling 
the 1987 criteria, who were consecutively included in the Leiden 
Early Arthritis Clinic, were studied. According to treatment 
in routine care, patients included between 1993 and 2000 
received initial treatment with only non-steroidal anti-inflam-
matory drugs or mild disease-modifying antirheumatic drugs 
(eg, penicillamine, gold, hydroxychloroquine). Patients included 
between 2001 and 2016 were treated with early intensive treat-
ment with methotrexate as first-line treatment. Treat-to-target 
became routine during this period as well. Mortality data were 
obtained from the civic registries on 1 June 2018. Mortality was 
compared with the general population in the Netherlands with 
SMRs adjusted for birth year, gender and calendar year. SMRs 
were determined for both treatment strategies, after stratifica-
tion for follow-up duration (0–5 years, 5–10 years, >10 years) 
and disease subset (ACPA status).
Baseline characteristics are shown in table 1. Two hundred 
and forty-eight patients died during follow-up. SMRs increased 
during follow-up and excess mortality became evident after 10 
years of disease (0–5 years SMR 0.55 (0.41–0.73); 5–10 years 
1.08 (0.87–1.33) and >10 years 1.39 (1.15–1.66); figure 1A). 
Stratification for disease subset revealed that a decreased 
mortality was observed within ACPA-negative RA (SMR 0.80 
(0.67–0.96)) and an increased mortality within ACPA-positivity 
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Table 1 Baseline characteristics of patients with RA treated without 
and with early intensive treatment
No early intensive 
treatment
Early intensive treatment
(n=353) (n=945)
Inclusion period 1993–2000 2001–2016
Women, n (%) 238 (67) 620 (66)
Age in years, mean (SD) 56 (16) 58 (15)
Symptom duration, days 
median (IQR)
136 (75–279) 117 (58–234)
Current smoker, n (%) 98 (30) 211 (25)
ESR, median (IQR) 37 (21–58) 29 (14–45)
66-SJC, median (IQR) 10 (5–16) 6 (3–11)
RF-positive, n (%) 193 (55) 543 (59)
ACPA-positive, n (%) 199 (56) 456 (51)
ACPA, anti-citrullinated peptide antibody; ESR, erythrocyte sedimentation rate; RF, 
rheumatoid factor; SJC, swollen joint count.
Figure 1 Mortality of patients with rheumatoid arthritis (RA) compared with the general population, stratified for follow-up duration (A), disease 
subset characterised by anticitrullinated protein antibody (ACPA) status (B), early intensive treatment (IT) (C) and these variables combined (D and E), 
showing that excess mortality has normalised by early intensive treatment in ACPA-negative RA but not in ACPA-positive RA.
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RA (SMR 1.38 (1.15–1.63); figure 1B). Comparing the two 
treatment strategies without considering follow-up duration and 
ACPA status revealed that early intensive treatment was associated 
with a decrease in mortality compared with the general popula-
tion (SMR 0.77 (0.63–0.93)), in contrast to group without early 
intensive treatment (SMR 1.23 (1.05–1.44); figure 1C). This is 
concordance with the findings from Poppelaars et al. Subsequent 
stratification for follow-up duration and ACPA-status showed 
that excess mortality became apparent after 10 years of disease 
in ACPA-negative RA without early intensive treatment and that 
early intensive treatment had normalised this excess mortality. 
In ACPA-positive RA, in contrast, excess mortality emerged after 
5 years of follow-up and was not influenced by early intensive 
treatment.
In conclusion, sufficient follow-up duration and stratification 
for relevant disease subsets are important to disentangle the 
effects of treatment on mortality. Our data from a large cohort 
of patients with RA with up to 25 years follow-up showed that 
excess mortality has resolved since the introduction of early 
intensive treatment in ACPA-negative RA, but excess mortality 
remains an issue in ACPA-positive RA. This underlines that RA 
consists of two types with differences in treatment response and 
long-term outcome and that additional efforts are still needed 
to reduce the increased risk of early death in ACPA-positive RA.
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